title: Review of teriflunomide and its potential in the treatment of multiple sclerosis.
abstract: In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.
authors: Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany.
authors: Clemens
authors: C
authors: Warnke
authors: Gerd
authors: G
authors: Meyer zu Hörste
authors: Hans-Peter
authors: HP
authors: Hartung
authors: Olaf
authors: O
authors: Stüve
authors: Bernd C
authors: BC
authors: Kieseier